Area of research
Physiology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Medicine, Asthma, Dupilumab, Internal medicine, COPD, and Exhaled nitric oxide.
Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with Asthma
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma
Real-world effectiveness of dupilumab in patients with asthma
Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose
La FeNO, un marqueur pronostique et prédictif potentiel de déclin de la fonction respiratoire chez des patients atteints d’asthme modéré à sévère non contrôlé : LIBERTY ASTHMA QUEST
Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction
FeNO as a Potential Prognostic and Predictive Marker of Lung Function Decline in Patients with Uncontrolled, Moderate-to-Severe Asthma: LIBERTY ASTHMA QUEST
Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of ICS dose
Long-Term Efficacy of Dupilumab in Quadrants of Elevated- vs Low- Type 2 Biomarker Patients With Uncontrolled, Moderate-to-Severe Asthma: LIBERTY ASTHMA TRAVERSE
Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Asthma with Elevated Type 2 Biomarkers and Fixed Airflow Obstruction
Effect of Dupilumab on Lung Function Parameters in Oral Corticosteroid-Dependent Patients With Asthma Enrolled in LIBERTY ASTHMA TRAVERSE
Biomarkers associated with lung function decline and dupilumab response in patients with moderate-to-severe asthma
P48 Long-term efficacy of dupilumab in patients with moderate-to-severe asthma in the LIBERTY ASTHMA TRAVERSE open-label extension study: improvements in asthma control and health-related quality of life
S136 Long-term safety and efficacy of dupilumab in patients with asthma: LIBERTY ASTHMA TRAVERSE open-label extension study
Long-Term 3-Year Efficacy of Dupilumab in QUEST Patients Enrolled in LIBERTY ASTHMA TRAVERSE
Dupilumab Shows Sustained Efficacy and Improvements in Asthma Control and Health-Related Quality of Life in Patients with Moderate-to-Severe Asthma: LIBERTY ASTHMA TRAVERSE
PBI1 Liberty Asthma Traverse Dupilumab Shows Sustained Efficacy and Improvements in Asthma Control and Health-Related Quality of Life (HRQOL) in Patients with Moderate-to-Severe Asthma
S84 Long-term efficacy of dupilumab: 3-year data of QUEST patients with moderate-to-severe asthma enrolled in LIBERTY ASTHMA TRAVERSE
Efficacité à long terme à trois ans du dupilumab chez les patients QUEST recrutés dans l’étude LIBERTY ASTHMA TRAVERSE
Late Breaking Abstract - Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE
Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease
Clinical Approach to the Therapy of Asthma-COPD Overlap
Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis
Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 Subjects
Sex-Based Genetic Association Study Identifies <i>CELSR1</i> as a Possible Chronic Obstructive Pulmonary Disease Risk Locus among Women
Sex-specific features of emphysema among current and former smokers with COPD
A genome-wide analysis of the response to inhaled β2-agonists in chronic obstructive pulmonary disease
The clinical and genetic features of COPD-asthma overlap syndrome
Radiological correlates and clinical implications of the paradoxical lung function response to β2 agonists: an observational study